YEEDO News
-
GOOD NEWS丨Yeedozencom Helps China's First Independently Developed MEK Inhibitor Tunlametinib Receive NMPA Approval for Marketing
Yeedozencom Helps China's First Independently Developed MEK Inhibitor Tunlametinib Receive NMPA Approval for Marketing2024-04-01 -
GOOD NEWS丨Yeedozencom assisted Singqi in the approval of 0.01% atropine sulfate eye drops
Yeedozencom assisted Singqi in the approval of 0.01% atropine sulfate eye drops2024-04-01 -
GOOD NEWS丨Congratulations to Guangzhou Green Cross on the approval of Dexamethasone Palmitate Injection
GOOD NEWS丨Congratulations to Guangzhou Green Cross on the approval of Dexamethasone Palmitate Injection2024-04-01 -
GOOD NEWS丨Congratulations on the approval of Lidocaine Hydrochloride Gel
Congratulations on the approval of Lidocaine Hydrochloride Gel2024-04-01 -
Good News丨YEEDOZENCOM and Guangzhou Green Cross reached a strategic cooperation
On November 10,2023, YEEDOZENCOM and Guangzhou Green Cross signed a strategic cooperation agreement.2023-11-21 -
Good News丨Congratulations on the IND approval of[¹⁸F]BF₃-BPA Injection of BoomRay
On August 29,2023, BoomRay Pharmaceuticals (hereinafter referred to as "BoomRay") , the registered partner of Yeedo, received a notice from the CDE that [¹⁸ F] BF ₃ -BPA injection (BR-02) developed by BoomRay obtained IND approval. Yeedo warmly congratulates BoomRay!2023-08-31